TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cost Effectiveness of Early Interventions for Non-specific Low Back Pain: A Randomized Controlled Study Investigating Medical Yoga, Exercise Therapy and Evidence Based Advice
Brief Summary: This randomized controlled study will evaluate the cost effectiveness of a yoga intervention compared to two evidence based programs; giving advice to stay active and guided exercise sessions. The first active program includes a six week standardized strength training program where the participants are personally instructed by a trained physiotherapist. The second active program is a six week standardized kundalini yoga program with group sessions twice a week lead by an experienced yoga instructor. Both programs consist of two exercise sessions per week and lasts for six weeks. After six weeks the participants are instructed to continue practicing their program twice a week on their own. The hypothesis are that a kundalini yoga program as an early intervention for Low Back Pain (LBP) is more cost effective than the two other interventions studied.

Participants were recruited through the occupational health services and by advertisement in the local press. Study subjects eligible for inclusion were informed of the study either by health care personnel at the occupational health care centers or by a research assistant at the Karolinska Institutet. Subjects were informed that if they were eligible to participate in the study they would be given the opportunity to participate in one of three approaches for treatment of neck and back pain.


Options:
A: Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): N/A
B: Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Arm Label: Yoga; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): Yoga
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care book recommendations | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Self-care book recommendations; Assigned to Arm(s): 3
D: Arm Label: kUNDALINI YOGA; Type: EXPERIMENTAL; Interventions: Behavioral: Kundalini yoga | Arm Label: Self care advice to stay active; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self care advice | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Kundalini yoga; Assigned to Arm(s): kUNDALINI YOGA | Intervention Type: BEHAVIORAL; Name: Self care advice; Assigned to Arm(s): Self care advice to stay active | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Dose-optimized, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy Of Nwp09 In Pediatric Patients With Attention Deficit Hyperactivity Disorder (Adhd) In A Laboratory Classroom
Brief Summary: The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD


Options:
A: Arm Label: HLD200 (methylphenidate); Type: EXPERIMENTAL; Interventions: Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HLD200 methylphenidate hydrochloride (MPH) Capsules; Assigned to Arm(s): HLD200 (methylphenidate) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: NWP09 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NWP09; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRC-063 25 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 25 mg | Arm Label: PRC-063 45 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 45 mg | Arm Label: PRC-063 70 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 70 mg | Arm Label: PRC-063 85 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 85 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PRC-063 25 mg and Placebo, PRC-063 45 mg and Placebo, PRC-063 70 mg and Placebo, PRC-063 85 mg and Placebo, Placebo | Intervention Type: DRUG; Name: PRC-063 25 mg; Assigned to Arm(s): PRC-063 25 mg and Placebo | Intervention Type: DRUG; Name: PRC-063 45 mg; Assigned to Arm(s): PRC-063 45 mg and Placebo | Intervention Type: DRUG; Name: PRC-063 70 mg; Assigned to Arm(s): PRC-063 70 mg and Placebo | Intervention Type: DRUG; Name: PRC-063 85 mg; Assigned to Arm(s): PRC-063 85 mg and Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting
Brief Summary: Remote limb ischemic preconditioning (RIPC) has neuro-protective and anti-inflammatory effects on ischemia- reperfusion injury. As the extent of its effect is unknown, the investigators will use clinical outcome, serum biochemical markers and brain magnetic resonance imaging (MRI) to determine whether RIPC has neuro-protective and anti-inflammatory effects on patients undergoing carotid artery stenting.


Options:
A: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
B: Arm Label: Thrombolysis + Remote perconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Thrombolysis + remote perconditioning | Arm Label: Thrombolysis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Actilyse | Intervention Type: DRUG; Name: Actilyse; Assigned to Arm(s): Thrombolysis | Intervention Type: PROCEDURE; Name: Thrombolysis + remote perconditioning; Assigned to Arm(s): Thrombolysis + Remote perconditioning
C: Arm Label: bilateral limb ischemic preconditioning (BLIPC); Type: EXPERIMENTAL; Interventions: Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: bilateral limb ischemic preconditioning (Doctormate, IPC-906X); Assigned to Arm(s): bilateral limb ischemic preconditioning (BLIPC)
D: Arm Label: RIPC group; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischemic preconditioning, Procedure: Carotid Artery Stenting | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid Artery Stenting | Arm Label: Sham RIPC group; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham remote ischemic preconditioning, Procedure: Carotid Artery Stenting | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning; Assigned to Arm(s): RIPC group | Intervention Type: PROCEDURE; Name: Sham remote ischemic preconditioning; Assigned to Arm(s): Sham RIPC group | Intervention Type: PROCEDURE; Name: Carotid Artery Stenting; Assigned to Arm(s): Control group, RIPC group, Sham RIPC group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting
Brief Summary: Remote limb ischemic preconditioning (RIPC) has neuro-protective and anti-inflammatory effects on ischemia- reperfusion injury. As the extent of its effect is unknown, the investigators will use clinical outcome, serum biochemical markers and brain magnetic resonance imaging (MRI) to determine whether RIPC has neuro-protective and anti-inflammatory effects on patients undergoing carotid artery stenting.


Options:
A: Arm Label: RIPC group; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischemic preconditioning, Procedure: Carotid Artery Stenting | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid Artery Stenting | Arm Label: Sham RIPC group; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham remote ischemic preconditioning, Procedure: Carotid Artery Stenting | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning; Assigned to Arm(s): RIPC group | Intervention Type: PROCEDURE; Name: Sham remote ischemic preconditioning; Assigned to Arm(s): Sham RIPC group | Intervention Type: PROCEDURE; Name: Carotid Artery Stenting; Assigned to Arm(s): Control group, RIPC group, Sham RIPC group
B: Arm Label: Precondition; Type: EXPERIMENTAL; Interventions: Procedure: Precondition | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Precondition; Assigned to Arm(s): Precondition
C: Arm Label: Sham; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control | Arm Label: RIPC; Type: EXPERIMENTAL; Interventions: Procedure: Preconditioning | Intervention Type: PROCEDURE; Name: Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Sham
D: Arm Label: Remote ischaemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischaemic preconditioning | Arm Label: Control to remote preconditioning group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic preconditioning

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012
Brief Summary: RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of tremelimumab in malignant mesothelioma (MM) patients.

PURPOSE: The proposed study MESOT-TREM-2012 aims to explore the efficacy of a more intensive schedule of treatment with tremelimumab in 29 MM patients. Subjects will receive investigational product every 4 weeks (wks) for 6 doses, followed by doses every 12 wks until confirmed disease progression.


Options:
A: Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pemetrexed disodium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab; Assigned to Arm(s): 2
C: Arm Label: single arm with Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm with Tremelimumab
D: Arm Label: single arm of Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm of Tremelimumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Sympathetic Denervation in Patients With Mild Refractory Hypertension
Brief Summary: The purpose of this study is to examine the benefit of renal sympathetic denervation in patients with mild refractory hypertension


Options:
A: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Device: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA) | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Other: Sham procedure | Intervention Type: DEVICE; Name: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA); Assigned to Arm(s): Renal sympathetic denervation | Intervention Type: OTHER; Name: Sham procedure; Assigned to Arm(s): Sham procedure
B: Arm Label: group Co; Type: ACTIVE_COMPARATOR; Interventions: Device: The HOTMAN® System | Arm Label: group RDN; Type: ACTIVE_COMPARATOR; Interventions: Procedure: The SymplicityTM Renal Denervation System | Intervention Type: PROCEDURE; Name: The SymplicityTM Renal Denervation System; Assigned to Arm(s): group RDN | Intervention Type: DEVICE; Name: The HOTMAN® System; Assigned to Arm(s): group Co
C: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: Renal sympathetic denervation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Renal sympathetic denervation; Assigned to Arm(s): Renal sympathetic denervation
D: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation | Intervention Type: DEVICE; Name: Renal Denervation; Assigned to Arm(s): Renal Denervation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Sympathetic Denervation in Patients With Mild Refractory Hypertension
Brief Summary: The purpose of this study is to examine the benefit of renal sympathetic denervation in patients with mild refractory hypertension


Options:
A: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Device: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA) | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Other: Sham procedure | Intervention Type: DEVICE; Name: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA); Assigned to Arm(s): Renal sympathetic denervation | Intervention Type: OTHER; Name: Sham procedure; Assigned to Arm(s): Sham procedure
B: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
C: Arm Label: Renal Denervation plus Medications; Type: EXPERIMENTAL; Interventions: Device: Radiofrequency ablation catheter, Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Arm Label: Medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Intervention Type: DEVICE; Name: Radiofrequency ablation catheter; Assigned to Arm(s): Renal Denervation plus Medications | Intervention Type: DRUG; Name: Amlodipine, losartan potassium and hydrochlorothiazide; Assigned to Arm(s): Medications, Renal Denervation plus Medications
D: Arm Label: Control group; Type: OTHER; Interventions: Procedure: Renal denervation | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Procedure: Renal denervation | Intervention Type: PROCEDURE; Name: Renal denervation; Assigned to Arm(s): Control group, Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine Replacement for Smoking Cessation During Pregnancy
Brief Summary: This is a clinical trial to determine if the nicotine inhaler in combination with counseling will help pregnant women quit smoking, and whether it is safe when compared to placebo (an inactive inhaler).


Options:
A: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT
B: Intervention Type: BEHAVIORAL; Name: Nicotine Replacement Therapy; Assigned to Arm(s): N/A
C: Arm Label: Nicotrol Inhaler; Type: EXPERIMENTAL; Interventions: Drug: Nicotrol Inhaler | Arm Label: Placebo Inhaler; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaler | Intervention Type: DRUG; Name: Nicotrol Inhaler; Assigned to Arm(s): Nicotrol Inhaler | Intervention Type: DRUG; Name: Placebo Inhaler; Assigned to Arm(s): Placebo Inhaler
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 2 mg nicotine polacrilex | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 2 mg nicotine polacrilex; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine Replacement for Smoking Cessation During Pregnancy
Brief Summary: This is a clinical trial to determine if the nicotine inhaler in combination with counseling will help pregnant women quit smoking, and whether it is safe when compared to placebo (an inactive inhaler).


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 2 mg nicotine polacrilex | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 2 mg nicotine polacrilex; Assigned to Arm(s): B
B: Arm Label: Nicotrol Inhaler; Type: EXPERIMENTAL; Interventions: Drug: Nicotrol Inhaler | Arm Label: Placebo Inhaler; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaler | Intervention Type: DRUG; Name: Nicotrol Inhaler; Assigned to Arm(s): Nicotrol Inhaler | Intervention Type: DRUG; Name: Placebo Inhaler; Assigned to Arm(s): Placebo Inhaler
C: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine versus placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: nicotine versus placebo | Intervention Type: DRUG; Name: nicotine versus placebo; Assigned to Arm(s): A, B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
Brief Summary: This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA).

This research is being done to compare the efficacy of HP802-247 plus compression therapy against Vehicle plus compression therapy in achieving complete wound closure over the 12-week treatment period. Vehicle looks the same as HP802-247 but contains no cells.


Options:
A: Arm Label: Keratin dressings; Type: EXPERIMENTAL; Interventions: Device: Keratin dressings | Arm Label: Usual care dressings; Type: ACTIVE_COMPARATOR; Interventions: Device: Usual care dressings | Intervention Type: DEVICE; Name: Keratin dressings; Assigned to Arm(s): Keratin dressings | Intervention Type: DEVICE; Name: Usual care dressings; Assigned to Arm(s): Usual care dressings
B: Arm Label: HP802-247 plus compression therapy; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: HP802-247 Vehicle plus compression therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: HP802-247 Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 plus compression therapy | Intervention Type: OTHER; Name: HP802-247 Vehicle; Assigned to Arm(s): HP802-247 Vehicle plus compression therapy
C: Arm Label: HP802-247; Type: EXPERIMENTAL; Interventions: Biological: HP-802-247 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vehicle | Intervention Type: BIOLOGICAL; Name: HP-802-247; Assigned to Arm(s): HP802-247 | Intervention Type: BIOLOGICAL; Name: Vehicle; Assigned to Arm(s): Vehicle
D: Arm Label: HP802-247; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 | Intervention Type: BIOLOGICAL; Name: Vehicle; Assigned to Arm(s): Vehicle

Answer: C